Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE guidelines [CG164], www.NICE.org.uk (2013, accessed 11 August 2015).
2.
SmithSGSestakIForsterA. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol2016; 27: 575–590.
3.
Smith SG, Side L, Meisel SF, et al. Clinician-reported barriers to implementing breast cancer chemoprevention in the UK: a qualitative investigation. Public Health Genomics 2016; 19: 239–249.
4.
NayfieldSKarpJEFordLG. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst1991; 83: 1450–1459.
5.
CuzickJPowlesTVeronesiU. Overview of the main outcomes in breast-cancer prevention trials. Lancet2003; 361: 296–300.
6.
MartinoSCauleyJABarrett-ConnorE. CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst2004; 96: 1751–1761.
7.
Barrett-ConnorEMoscaLCollinsP. Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med2006; 355: 125–137.
8.
VogelVGCostantinoJPWickerhamDL. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA2006; 295: 2727–2741.
9.
CuzickJSestakIBonanniB. Selective estrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet2013; 381: 1827–1834.
10.
CuzickJSestakICawthornS. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol2015; 16: 67–75.
11.
DowsettMCuzickJIngleJ. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol2010; 28: 509–518.
12.
GossPEIngleJNAles-MartinezJE. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med2011; 364: 2381–2391.
13.
CuzickJSestakIForbesJF. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet2014; 383: 1041–1048.
14.
MavaddatNBarrowdaleDAndrulisIL. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev2012; 21: 134–147.
HartmannLCLindonNM. The role of risk-reducing surgery in hereditary Breast and ovarian cancer. N Engl J Med2016; 374: 454–468.
17.
FisherB. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst2005; 97: 1652–1662.
18.
PowlesTJHickishTKanisJA. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol1996; 14: 78–84.
19.
VehmanenLElomaaIBlomqvistC. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol2006; 24: 675–680.
20.
SverrisdóttirAFornanderTJacobssonH. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol2004; 22: 3694–3699.
21.
RunowiczCDCostantinoJPWickerhamDL. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). Am J Obstet Gynecol2011; 205: 535e1–535e5.
22.
DeCensiABonanniBMaisonneuveP. for the Italian HOT Study Group. A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Ann Oncol2013; 24: 2753–2760.
23.
Singer BR, McLauchlan GJ, Robinson CM, et al. Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 998; 80: 243–248.
SilversteinMDHeitJAMohrDN. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Int Med1998; 158: 585–593.
26.
Menopause: diagnosis and management. NICE guidelines [NG23] www.NICE.org.uk (accessed 11 December 2016).
